Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study
Background/Aims: Escherichia coli Nissle 1917 (EcN) alone therapy is as effective as mesalamine in inducing and maintaining remission in ulcerative colitis (UC). The efficacy and safety of EcN in combination with standard therapies have not been studied. This study examined the changes in the inflam...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Jin Publishing & Printing Co.
2021-01-01
|
Series: | The Korean Journal of Gastroenterology |
Subjects: | |
Online Access: | http://www.kjg.or.kr/journal/view.html?uid=5659&vmd=Full |
_version_ | 1819297440131448832 |
---|---|
author | Gyu Man Oh Won Moon Kwang Il Seo Kyoungwon Jung Jae Hyun Kim Sung Eun Kim Moo In Park Seun Ja Park |
author_facet | Gyu Man Oh Won Moon Kwang Il Seo Kyoungwon Jung Jae Hyun Kim Sung Eun Kim Moo In Park Seun Ja Park |
author_sort | Gyu Man Oh |
collection | DOAJ |
description | Background/Aims: Escherichia coli Nissle 1917 (EcN) alone therapy is as effective as mesalamine in inducing and maintaining remission in ulcerative colitis (UC). The efficacy and safety of EcN in combination with standard therapies have not been studied. This study examined the changes in the inflammation markers and symptoms following the additional administration of EcN to patients showing the clinical remission of UC.
Methods: UC patients who received EcN after being in clinical remission for more than 3 months at Kosin University Gospel Hospital between 2013 and 2018 were evaluated through the retrospective medical-record-based review. The partial Mayo score, fecal calprotectin (FC), BMI, hemoglobin, serum cholesterol, serum albumin levels, and the safety profiles were examined at 3rd and 6th months after initiating EcN.
Results: Ninety-four patients were included. After 3 months of treatment, there was no significant change in FC (156.3 μg/g to 141.1 μg/g) (p=0.653). On the other hand, partial Mayo score decreased significantly from 0.085 to 0.014 (p=0.025), and the bodyweight (p=0.001), BMI (p<0.001), hemoglobin (p=0.009), and cholesterol level increased (p=0.148). One patient (1.1%) experienced a serious adverse event with UC flare-up, and 14 patients (14.9%) discontinued EcN due to adverse events; all developed within 3 months.
Conclusions: Additional administration of EcN to clinically remission-attained UC patients may improve the UC symptoms without changing the FC levels. EcN-associated adverse events develop within the early few weeks. |
first_indexed | 2024-12-24T05:14:02Z |
format | Article |
id | doaj.art-61ec0f6fc6904d0595217f4a2d99cac1 |
institution | Directory Open Access Journal |
issn | 1598-9992 2233-6869 |
language | English |
last_indexed | 2024-12-24T05:14:02Z |
publishDate | 2021-01-01 |
publisher | Jin Publishing & Printing Co. |
record_format | Article |
series | The Korean Journal of Gastroenterology |
spelling | doaj.art-61ec0f6fc6904d0595217f4a2d99cac12022-12-21T17:13:36ZengJin Publishing & Printing Co.The Korean Journal of Gastroenterology1598-99922233-68692021-01-01771122110.4166/kjg.2020.0119Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort StudyGyu Man Oh0Won Moon1https://orcid.org/0000-0002-3963-8680Kwang Il Seo2Kyoungwon Jung3Jae Hyun Kim4Sung Eun Kim5Moo In Park6Seun Ja Park7Department of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaDepartment of Internal Medicine, Kosin University College of Medicine, Busan, KoreaBackground/Aims: Escherichia coli Nissle 1917 (EcN) alone therapy is as effective as mesalamine in inducing and maintaining remission in ulcerative colitis (UC). The efficacy and safety of EcN in combination with standard therapies have not been studied. This study examined the changes in the inflammation markers and symptoms following the additional administration of EcN to patients showing the clinical remission of UC. Methods: UC patients who received EcN after being in clinical remission for more than 3 months at Kosin University Gospel Hospital between 2013 and 2018 were evaluated through the retrospective medical-record-based review. The partial Mayo score, fecal calprotectin (FC), BMI, hemoglobin, serum cholesterol, serum albumin levels, and the safety profiles were examined at 3rd and 6th months after initiating EcN. Results: Ninety-four patients were included. After 3 months of treatment, there was no significant change in FC (156.3 μg/g to 141.1 μg/g) (p=0.653). On the other hand, partial Mayo score decreased significantly from 0.085 to 0.014 (p=0.025), and the bodyweight (p=0.001), BMI (p<0.001), hemoglobin (p=0.009), and cholesterol level increased (p=0.148). One patient (1.1%) experienced a serious adverse event with UC flare-up, and 14 patients (14.9%) discontinued EcN due to adverse events; all developed within 3 months. Conclusions: Additional administration of EcN to clinically remission-attained UC patients may improve the UC symptoms without changing the FC levels. EcN-associated adverse events develop within the early few weeks.http://www.kjg.or.kr/journal/view.html?uid=5659&vmd=Fullinflammatory bowel diseasescolitisulcerativeprobioticsprebiotics |
spellingShingle | Gyu Man Oh Won Moon Kwang Il Seo Kyoungwon Jung Jae Hyun Kim Sung Eun Kim Moo In Park Seun Ja Park Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study The Korean Journal of Gastroenterology inflammatory bowel diseases colitis ulcerative probiotics prebiotics |
title | Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study |
title_full | Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study |
title_fullStr | Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study |
title_full_unstemmed | Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study |
title_short | Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study |
title_sort | therapeutic potential of escherichia coli nissle 1917 in clinically remission attained ulcerative colitis patients a hospital based cohort study |
topic | inflammatory bowel diseases colitis ulcerative probiotics prebiotics |
url | http://www.kjg.or.kr/journal/view.html?uid=5659&vmd=Full |
work_keys_str_mv | AT gyumanoh therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT wonmoon therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT kwangilseo therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT kyoungwonjung therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT jaehyunkim therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT sungeunkim therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT mooinpark therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy AT seunjapark therapeuticpotentialofescherichiacolinissle1917inclinicallyremissionattainedulcerativecolitispatientsahospitalbasedcohortstudy |